UBS initiated coverage of Oscar Health with a Neutral rating and $23 price target The firm sees Oscar Health executing on its growth initiatives, but at a more conservative level, balanced against a valuation that largely captures this, the analyst tells investors in a research note. UBS sees a three-year revenue compound annual growth rate of 15% from 2025-2027, and for 2025 sees revenue of $11.1B and EPS of 59c, but is taking a more conservative view in 2026/2027, with revenue of $11.6B/$13.6B and EPS of $1.03/$1.79.